Halozyme Therapeutics, Inc. (HALO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 1.82M | 5.69M | 1963 |
| Ms. Nicole LaBrosse | Senior VP & CFO | 849.36k | -- | 1983 |
| Dr. Michael J. LaBarre Ph.D. | Senior VP & Chief Technical Officer | 843.89k | 2.6M | 1964 |
| Mr. Mark Snyder Esq. | Senior VP & Chief Legal Officer | 912.87k | -- | -- |
| Ms. Cortney Caudill M.B.A. | Chief Operations Officer | -- | -- | -- |
| Ms. Tram Bui | Head of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Amy Marinne Fox | Senior Vice President of Human Resources | -- | -- | -- |
Halozyme Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 373
Description
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Corporate Governance
Recent Events
- Mar 15, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 04, 2024PRE 14A: Proxy StatementsSee Full Filing
- Feb 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 01, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 23, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing